Crystagen Research

Crystagen is a synthetic short peptide sold as a research chemical. Its sequence is written Glu-Asp-Pro, or EDP. This page reviews the entire published record for Crystagen. That record is one paper. The page contains no dosing or administration information.

Identity

Crystagen is a defined synthetic tripeptide, Glu-Asp-Pro ^[1]. It also appears under the code name T-36. An NLM supplementary concept record exists for glutamyl-aspartyl-proline, carrying the entry terms Glu-Asp-Pro and "T-36 tripeptide" ^[2].

Two database cautions matter here. The NLM record carries no "Crystagen" entry term, and PubChem returns no record under that name ^[2]. There is no CAS registry number for this compound. The sequence code is the only reliable handle for it in either database. The PubChem record titled Glu-Asp-Pro, CID 145455337, carries D-proline stereochemistry despite its L- title, while the all-L structure sits in an unnamed record, CID 23624313 ^[2].

The two authority sources also disagree about what the molecule does. The originating group's own table, in a 2022 review, labels EDP an immunoprotector ^[1]. The NLM scope note describes it as a peptide that stimulates proliferation of skin cells ^[2]. Neither statement is an experimental result. They are incompatible labels, and nothing published resolves them.

The entire published evidence

Crystagen has exactly one record in all of PubMed ^[3][4]. It is a Russian-language paper in Advances in Gerontology, 2014, with an English abstract only and no DOI ^[3].

In that paper the compound is described only as a "short peptide," and no sequence is given ^[3]. The paper therefore does not itself confirm that the substance tested was EDP.

The reported result is partly negative. The abstract states that Crystagen activates B-cells of the immune system, and that the peptide does not cause cell renewal in spleen as it ages ^[3]. The negative half is not a caveat. It is half of the finding.

This is not a human study ^[5]. The record states no species and carries no MeSH substance terms, and the model is inferred to be organotypic spleen culture rather than dosing of a live animal ^[3]. Methods, controls, blinding and statistics cannot be assessed from an English abstract alone.

Who produced it

That single paper comes from the originating network, with Khavinson as senior author and Linkova and Chalisova as co-authors ^[3]. One of one indexed Crystagen record is in-network ^[4]. No independent literature on Crystagen exists in any language PubMed indexes.

As family background: the people who discovered, patented, manufacture and sell these peptides produced nearly all of the published work on them ^[4]. For this compound that concentration is total.

What has not been studied

There is no human study of Crystagen of any kind ^[5]. No clinical trial of it is registered on ClinicalTrials.gov ^[6].

No lifespan or longevity data exists for Crystagen ^[4]. No human pharmacokinetic data has been published, and no animal pharmacokinetic study of it was located ^[7]. Nothing is known about absorption, persistence or distribution.

Crystagen (EDP) is Cortagen (AEDP) without its leading alanine ^[1]. Several compounds in this family are nested sub-sequences of one another in the same way. There is no published basis on which to tell a reader what functionally distinguishes Crystagen from a sibling differing by one residue.

Longevity and mortality figures that circulate for "Khavinson peptides" generally belong to other substances, including crude bovine extracts. None of that is Crystagen data.

Crystagen is supplied as a laboratory research chemical.

References

1. 1

   Khavinson V, et al. International Journal of Molecular Sciences. 2022. PMID 35887081. DOI: 10.3390/ijms23147733. (Review. Table 2 gives Crystagen = EDP. The same table sets out the ED- series and the AED- series as alanine plus each ED- member, making AEDP alanine plus Crystagen. Note the paper spells Cortagen as "Korthagen," so a text search for the usual spelling returns nothing.)
2. 2

   NLM MeSH supplementary concept C000605987 and PubChem name and structure queries, run 27 August 2026. (Entry terms glutamyl-aspartyl-proline, Glu-Asp-Pro and "T-36 tripeptide"; scope note "a synthetic peptide that stimulates proliferation of skin cells"; no "Crystagen" entry term; no PubChem record under the name Crystagen; no CAS; named Glu-Asp-Pro record CID 145455337 carries D-proline, all-L structure is unnamed CID 23624313.)
3. 3

   Chervyakova NA, et al. Advances in Gerontology (Uspekhi Gerontologii). 2014;27(1):224-228. PMID 28976144. (Russian, English abstract only, no DOI. The sole PubMed record naming Crystagen. Compound called a "short peptide" with no sequence stated. Linkova, Chalisova and Khavinson are co-authors. PubMed renders the first author's surname with a Cyrillic C.)
4. 4

   PubMed E-utilities record counts and authorship analysis, run 27 August 2026. (Crystagen bare-term count 1; one of one record in-network; no lifespan or longevity record for Crystagen; corpus-level concentration of the family literature in the originating group.)
5. 5

   PubMed E-utilities human-evidence searches, run 27 August 2026. (No human study of Crystagen located under name, sequence or clinical search terms; Crystagen survives the stricter no-human-data test applied to this family.)
6. 6

   ClinicalTrials.gov API v2 registry query, run 27 August 2026. (Zero hits for Crystagen; no registered trial.)
7. 7

   PubMed E-utilities pharmacokinetic absence searches, run 27 August 2026. (No pharmacokinetic study of Crystagen located in humans or in animals.)